Vetter, a global CDMO, plans to move and expand its Development Services site from Skokie, IL, to Des Plaines, further investing in its U.S. footprint. The company also plans additional major investment in its commercial business in Southwest Germany, to complement its capacity expansions in Ravensburg and Langenargen, which are currently underway. This adds more capacity for future customers as the injectable industry experiences a rise in outsourcing development, manufacturing, assembly and packaging needs to CDMOs. 
 
“As an independent and family-owned company, we prioritize thoughtful and strategic planning to support our long-term business growth,” said Udo J. Vetter, Chairman of the Advisory Board and member of the owner family. “With these investments we reaffirm our commitment on both continents and enable that Vetter Pharma will continue to be part of a growing market in the future.”
 
Vetter acquired the Des Plaines site a few years ago. The recent decision to further expand aims elevate Vetter Development Services to support growing customer needs at the current Skokie site, as well as at the company’s clinical manufacturing site in Rankweil, Austria. 
 
This development plan involves a construction project at the Des Plaines site and the relocation and expansion of Vetter Development Services U.S. from the Illinois Science and Technology Park over the next few years. New buildings for clinical manufacturing and related services will be constructed. The move will effectively double the capacity of Vetter Development Services in the U.S. and provide ample space for future expansion opportunities.
 
Vetter plans an additional investment of several hundred million Euro for a commercial production site in Saarlouis, Saarland. This aims to support access to an existing network of suppliers and the use of the company’s internal infrastructure. Pharmaceutical production at the site is expected to start by 2030 and Vetter is planning to create up to 2,000 new local jobs in the years to come. 
 
Managing Director Thomas Otto said, “After careful consideration, Germany, and Saarland in particular, prove to be the location with the best-fitting conditions for expanding our commercial operations. In addition to the existing and growing competencies and capacities at and around our sites in Ravensburg, we will be able to further expand our range of services. We are taking responsibility for patients and customers worldwide who rely on our high level of quality.”